Relese

Your clinician customized this product information just for you

Relese, per square centimeter

Relese™ is comprised of dehydrated human amniotic membrane obtained from donated placental tissue.

INTENDED USE: Relese™ is a sheet skin substitute product that contains non-viable cells and is intended for use as a selective barrier and to protect wounds from the surrounding environment for chronic and acute wounds including dermal ulcers and other defects.

CLAIMED BENEFITS: The processed membrane is dehydrated, fenestrated and cut into various sizes, and presented in a sterilized, dehydrated sheet graft form. The processing of Relese™ preserves all layers of the placental membrane and maintains the 3D physiologic architecture of the natural barrier membrane. This triple layer barrier containing amnion, intermediate layer, and chorion provides a selective barrier and protection between wound and the surrounding environment.

OPTION: Relese™ is offered in a variety of sizes from 2x2 cm to 6x8 cm sheets. The amount of Relese™ used will be determined by the treating health care provider, based on the size of the wound. Relese™ can be applied over the wound area either wet or dry. If hydration is preferred, sterile solution is used to hydrate the graft after placement on the wound site. Relese™ is supplied as a terminally sterilized dehydrated human tissue allograft derived from human amnion and chorion membrane. Relese™ should be maintained in its original packaging and stored at ambient temperature (0°C to 38°C) until ready to use. Relese™ is for single patient use only.

Product Information

The addition of Skin Substitutes or Cellular or Tissue Based Products (CTPs) to certain wounds may afford a healing advantage over dressings and conservative treatments when these options appear insufficient to affect complete healing, after at least a 30 day period of comprehensive conservative therapy. There are currently a wide variety of bioengineered products available for soft tissue coverage to affect closure. • Human skin allografts are derived from donated human skin (cadavers) • Allogeneic matrices are derived from human tissue (fibroblasts or membrane) • Composite matrices are derived from human keratinocytes, fibroblasts and xenogeneic collagen • Acellular matrices are derived from xenogeneic collagen or tissue

Pricing and Suppliers

Is it covered by Medicare Part B?

Medicare covers the application of Cellular and Tissue Based Products (CTPs) for chronic Wounds, which are defined as wounds that do not respond to standard wound treatment for at least a 30 day period during organized comprehensive conservative therapy. Medicare has guidelines that establish what is considered medically necessary and how often an item can be used.

How can I purchase this product?

For Medicare to cover this product, it needs to be ordered and applied by your clinician. A patient cannot purchase it directly from a Durable Medical Equipment (DME) store and receive reimbursement for it.

The table below shows highest and lowest Medicare pricing across the country

Description	Medicare DME co-payment Min / Max
	$0.00 / $0.00

Estimated out-of-pocket cost:

If your insurance does not cover this product, you can purchase it directly from any store. A list of online stores and prices is provided below for your convenience. For updated prices, find it on the internet at https://woundreference.com/app/product?id=3390

Other Stores

* Indicates whether store accepts Medicare or commercial insurance, but may not apply to this specific product. See coding, coverage and reimubursement for more information.

The information on this handout is for your convenience and educational purposes only. All product claims and specifications are those of the product suppliers. It does not constitute medical advice or a guarantee for reimbursement. Prices may have changed and suppliers may not have product in stock. Please confirm accuracy and appropriateness of information with insurance carrier and product supplier. Clinician and WoundReference assume no liability for inaccuracies or misstatements about products and insurance coverage.